openPR Logo
Press release

Irritable Bowel Syndrome Treatment Market To Receive Overwhelming Hike In Revenues By 2026 And The Key Players Are Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Valeant Pharmaceuticals International

06-22-2019 02:00 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Irritable Bowel Syndrome Treatment

Irritable Bowel Syndrome Treatment

The global irritable bowel syndrome treatment market was valued at US$ 726.1 million in 2016 and is expected to witness a robust CAGR of 12.9% over the forecast period (2017-2025). The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet to be established. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe.

Download The PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/506

Mild symptoms do not significantly affect the quality of life. However, severe symptoms are more frequent and intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or prebiotics depending on the situation.

Market Dynamics

The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable bowel syndrome, for which various companies such as Ironwood Pharmaceuticals, Inc. as well as NGOs conduct mass workshops for educating the people to incorporate healthy food habits as a major precaution towards prevention of IBS. Furthermore, major growth drivers for the irritable bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. According to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients suffering from gastrointestinal pain. The large population of stress and anxiety disorder patients are expected to fuel the growth of the global irritable bowel syndrome treatment market.

Robust pipeline with symptom specific indications and subsequent launches in the forecast period is expected to boost the market

According to International Foundation for Functional Gastrointestinal Disorders, 2016, worldwide prevalence of irritable bowel syndrome is around 10-15%. Furthermore, there are between 2.4 and 3.5 million annual physician visits for IBS in the U.S. according to the same source. According to the Anxiety and Depression Association of America, approximately one in five adults in the U.S. is suffering with irritable bowel syndrome. Irritable bowel syndrome shows a wide range of symptoms, so, the treatment is decided on predominance of the symptoms such as, in pain predominant patients, antispasmodic agents or tricyclic antidepressants are used. The prevalence of irritable bowel syndrome is predominant in female than in males. According to the International Foundation for Functional Gastrointestinal Disorders, 2 in 3 IBS sufferers are female. Some of the U.S. Food & Drug Administration approved drugs for relieving the symptoms associated with IBS are Lotronex (Alosetron), Amitiza (Lubiprostone), Linzess (Linclotide), and Xifaxan (Rifaximin).

Some major players operating in the irritable bowel syndrome treatment market are Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.

Discuss Your Queries With Our Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/506

Increase in levels of stress and adoption of sedentary lifestyle is expected to increase the prevalence of lifestyle disorders namely irritable bowel syndrome

The number of available irritable bowel syndrome drugs has increased over the last few years and new drugs have been approved for the treatment. North America accounts for the largest share in the global irritable bowel syndrome treatment market, followed by Europe and Asia-pacific, respectively. According to an article published in the Brandon Gaille in 2017, on an average, junk food accounts for 28.8% of the total caloric intake of an American. According to Centers for Disease Control and Prevention (CDC) in 2015, it was estimated that 1.3% of U.S. adults i.e. 3 million were reported to being diagnosed with IBD. Consumption of unhealthy food in large quantities raises the bar of probability for IBS acting as a driving factor for the global market growth. Furthermore, the companies are indulged in development, distribution and marketing agreements of irritable bowel syndrome treatment drugs in selective countries such as Japan and China which is expected to drive the growth of the Asia-Pacific irritable bowel syndrome treatment market. For, instance, Sucampo Pharmaceutical, Inc. collaborated with Herbin Gloria Pharmaceuticals to commercialize its product in China in 2015.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Irritable Bowel Syndrome Treatment Market To Receive Overwhelming Hike In Revenues By 2026 And The Key Players Are Abbott Laboratories, Synergy Pharmaceuticals, Sucampo Pharmaceuticals, Valeant Pharmaceuticals International here

News-ID: 1784801 • Views: 2600

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for IBS

Admissions Open for the PGDM program at SRMS IBS, Lucknow
Shri Ram Murti Smarak (SRMS) International Business School (IBS), Lucknow is currently accepting applications for its full-time, 2-year Post-Graduate Diploma in Management (PGDM). SRMS IBS offers its AICTE approved PGDM with specialisations offered in Banking, Marketing, Finance, International Business, Human Resource Management & Information Technology The B-school is part of the renowned SRMS Trust, which has continuously worked towards providing value-based education to its students across Medical, Engineering, and Management studies since
Cathay Pacific selects IBS Solution to help manage staff travel
Cathay Pacific has signed a multi-million dollar contract to implement IBS’ new generation solution, iFly Staff, to automate and improve the management of employee travel. iFly Staff will also be used for Cathay Pacific subsidiaries including sister airline Dragonair. The implementation of iFly Staff will result in an automated staff travel solution that supports the eligibility and entitlements offered to the airline’s employees and their dependants.
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning. This also includes consulting services concerning railway systems issues, such as travel
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011. The new bulkers, each with a capacity of 176,000 dwt, will be equipped
CoCoNet enhances MULTIVERSA IBS by OFTP access protocol
CoCoNet enhances the modern e-banking-platform MULTIVERSA IBS International Banking Server through an OFTP access channel (Odette File Transfer Protocol) for the data transmission between international banks and corporate customers. MULTIVERSA IBS is a modular and scalable platform for receiving and processing payment transaction data and delivering customer specific account information like account statements, intraday reports, returns and foreign exchange rate information. The initial situation at banks that now also offer
Maldivian uses IBS’ Passenger Services System
Trivandrum, 22 Sep 2008 – Maldivian, the national airline of Maldives, has gone live with IBS’ new-generation Passenger Service System, aiRES in the Software as a Service (SaaS) mode. The solution will help the airline manage its passenger reservations, inventory control, fares & ticketing, and departure control functions. Maldivian has chosen IBS’ solution for its cost-effectiveness, optimum fit, short implementation time and flexible features that include Web Distribution, GDS, and